Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.

Literature DB >> 31763994

The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.

Javid Moslehi^1,2, W Kimryn Rathmell^2,3.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2020 PMID： 31763994 PMCID： PMC6934228 DOI： 10.1172/JCI134813

Source DB: PubMed Journal: J Clin Invest ISSN： 0021-9738 Impact factor: 14.808

× No keyword cloud information.

19 in total

1. Targeted therapy for patients with renal-cell carcinoma.

Authors: Brian I Rini
Journal: Lancet Oncol Date: 2011-10-17 Impact factor: 41.316

2. Genetic evidence for high-altitude adaptation in Tibet.

Authors: Tatum S Simonson; Yingzhong Yang; Chad D Huff; Haixia Yun; Ga Qin; David J Witherspoon; Zhenzhong Bai; Felipe R Lorenzo; Jinchuan Xing; Lynn B Jorde; Josef T Prchal; RiLi Ge
Journal: Science Date: 2010-05-13 Impact factor: 47.728

Review 3. Cardiovascular Toxic Effects of Targeted Cancer Therapies.

Authors: Javid J Moslehi
Journal: N Engl J Med Date: 2016-10-13 Impact factor: 91.245

4. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors: A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal: Cell Date: 2001-10-05 Impact factor: 41.582

5. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Authors: Kevin D Courtney; Jeffrey R Infante; Elaine T Lam; Robert A Figlin; Brian I Rini; James Brugarolas; Naseem J Zojwalla; Ann M Lowe; Keshi Wang; Eli M Wallace; John A Josey; Toni K Choueiri
Journal: J Clin Oncol Date: 2017-12-19 Impact factor: 44.544

6. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors: M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal: Science Date: 2001-04-05 Impact factor: 47.728

7. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.

Authors: K M Lonergan; O Iliopoulos; M Ohh; T Kamura; R C Conaway; J W Conaway; W G Kaelin
Journal: Mol Cell Biol Date: 1998-02 Impact factor: 4.272

The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.

1. Targeted therapy for patients with renal-cell carcinoma.

2. Genetic evidence for high-altitude adaptation in Tibet.

Review 3. Cardiovascular Toxic Effects of Targeted Cancer Therapies.

4. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

5. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

6. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

7. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.

8. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis.

9. Purification and characterization of hypoxia-inducible factor 1.

10. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.

1. Special Issue: Hypoxia-Inducible Factors: Regulation and Therapeutic Potential.

2. Hypoxia regulates GR function through multiple mechanisms involving microRNAs 103 and 107.